The present invention discloses a process for preparing a functionalized choline chloride ionic liquid as defined in formula (I), and thereof use in an electrochemical energy storage device, as an electrolyte solution or an additive for a lithium ion battery and a supercapacitor. The ionic liquid electrolyte material has better biocompatibility, flame retardance, high ionic conductivity, low viscosity, and wide electrochemical window. ##STR00001## wherein R.sup.1 is selected from the group consisting of: (CH.sub.2═CH—(CH.sub.2).sub.n)—, CN(CH.sub.2).sub.n—, or R.sup.2.sub.3Si—; R.sup.2 is selected from CH.sub.3—(CH.sub.2).sub.m—, n is an integer selected from 1 to 3, m is an integer selected from 0 to 2; or one of R.sup.2 is (CH.sub.3).sub.3Si—O—. Anion A in Formula I is selected from the group consisting of: Cl.sup.−, Br.sup.−, I.sup.−, BF.sub.4.sup.−, NO.sub.3.sup.−, SO.sub.4.sup.2−, CF.sub.3COO.sup.−, CF.sub.3SO.sub.3.sup.−, (CF.sub.3SO.sub.2).sub.2N.sup.−, PF.sub.6.sup.−, BF.sub.2C.sub.2O.sub.4.sup.−, or B(C.sub.2O.sub.4).sub.2.sup.−.

The present invention discloses a process for preparing a functionalized choline chloride ionic liquid as defined in formula (I), and thereof use in an electrochemical energy storage device, as an electrolyte solution or an additive for a lithium ion battery and a supercapacitor. The ionic liquid electrolyte material has better biocompatibility, flame retardance, high ionic conductivity, low viscosity, and wide electrochemical window. ##STR00001## wherein R.sup.1 is selected from the group consisting of: (CH.sub.2═CH—(CH.sub.2).sub.n)—, CN(CH.sub.2).sub.n—, or R.sup.2.sub.3Si—; R.sup.2 is selected from CH.sub.3—(CH.sub.2).sub.m—, n is an integer selected from 1 to 3, m is an integer selected from 0 to 2; or one of R.sup.2 is (CH.sub.3).sub.3Si—O—. Anion A in Formula I is selected from the group consisting of: Cl.sup.−, Br.sup.−, I.sup.−, BF.sub.4.sup.−, NO.sub.3.sup.−, SO.sub.4.sup.2−, CF.sub.3COO.sup.−, CF.sub.3SO.sub.3.sup.−, (CF.sub.3SO.sub.2).sub.2N.sup.−, PF.sub.6.sup.−, BF.sub.2C.sub.2O.sub.4.sup.−, or B(C.sub.2O.sub.4).sub.2.sup.−.

The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release HNO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.

The present invention provides novel sotalol derivatives and pharmaceutical compositions containing the same that are are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.

The present invention provides novel sotalol derivatives and pharmaceutical compositions containing the same that are are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.

The present invention provides novel sotalol derivatives and pharmaceutical compositions containing the same that are are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.

The present invention provides novel sotalol derivatives and pharmaceutical compositions containing the same that are are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.

The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release HNO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.

The present invention provides novel sotalol derivatives and pharmaceutical compositions containing the same that are are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.

The present invention provides novel sotalol derivatives and pharmaceutical compositions containing the same that are are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.